Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

This trial is testing a combination of two drugs — selinexor and talazoparib — in people with hard-to-treat solid tumors, with a focus on triple-negative breast cancer (a type of breast cancer that lacks common hormone receptors). **You may be eligible if...** - You are 18 or older with advanced or metastatic solid tumors (or specifically triple-negative breast cancer in the expansion phase) - You have never taken talazoparib or selinexor before - Your cancer is still growing despite prior treatment - You are generally healthy enough to be up and around (ECOG performance status 0–1) - Your blood counts, kidney, and liver function are adequate - You can swallow tablets **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have had another cancer recently that is still detectable - You have active brain metastases (cancer in the brain) - You have significant nerve or mental health problems - You are currently on certain strong drug interactions (specific P-gp or BCRP inhibitors) - You have poorly controlled diabetes - You had major surgery in the past 28 days Talk to your doctor to see if this trial is right for you.